Invention Grant
US08178571B2 Unsubstituted and substituted 4-benzyl-1,3-dihydro-imidazole-2-thiones acting as specific or selective alpha2 adrenergic agonists and methods for using the same
失效
作为特异性或选择性α2肾上腺素能激动剂的未取代和取代的4-苄基-1,3-二氢 - 咪唑-2-硫酮及其使用方法
- Patent Title: Unsubstituted and substituted 4-benzyl-1,3-dihydro-imidazole-2-thiones acting as specific or selective alpha2 adrenergic agonists and methods for using the same
- Patent Title (中): 作为特异性或选择性α2肾上腺素能激动剂的未取代和取代的4-苄基-1,3-二氢 - 咪唑-2-硫酮及其使用方法
-
Application No.: US12849469Application Date: 2010-08-03
-
Publication No.: US08178571B2Publication Date: 2012-05-15
- Inventor: Todd M. Heidelbaugh , Ken Chow , Phong X. Nguyen , Daniel W. Gil , John E. Donello , Michael Garst , Larry A. Wheeler , John R. Cappiello
- Applicant: Todd M. Heidelbaugh , Ken Chow , Phong X. Nguyen , Daniel W. Gil , John E. Donello , Michael Garst , Larry A. Wheeler , John R. Cappiello
- Applicant Address: US CA Irvine
- Assignee: Allergan, Inc.
- Current Assignee: Allergan, Inc.
- Current Assignee Address: US CA Irvine
- Agency: Allergan, Inc.
- Agent Doina G. Ene; John E. Wurst
- Main IPC: A61K31/4164
- IPC: A61K31/4164 ; C07D233/84
Abstract:
Compounds of Formula 1 where the variables have the meaning defined in the specification are used to activate alpha2 adrenergic receptors. The compounds of Formula 1 are incorporated in pharmaceutical compositions and are used as medicaments in mammals, including humans, for treatment of diseases and or alleviations of conditions which are responsive to treatment by agonists of alpha2 adrenergic receptors.
Public/Granted literature
Information query
